Artificial Intelligence for Drug Safety Across the Lifecycle and Decision Type: A Scoping Review
Pharmaceuticals · 19.02.2026 · 19 (2) · 334
DOI: 10.3390/ph19020334 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 19.02.2026. Verfasst von Tae Woo Kim und 2 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Sunchon National University, Suncheon 57922, Republic of Korea. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 137 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Regional Innovation System & Education (RISE) program through the Jeollanamdo RISE center, funded by the Ministry of Education (MOE) and the Jeollanamdo, Repub….
Abstract (Originalsprache)
Background/Objectives: Artificial intelligence (AI) is increasingly applied to drug safety evaluation, yet evidence is dispersed across lifecycle stages and tasks. This scoping review aimed to (1) map how AI supports safety- and treatment-related decision types across the drug lifecycle, and (2) examine evaluation strategies used to assess model reliability for clinical or regulatory use.
Methods
Using Arksey and O’Malley’s framework, we searched a major database for studies published in the past decade that applied AI or machine learning to drug safety or medication-related decisions. After screening, we extracted data on lifecycle stage, decision type, AI methods, data sources, and evaluation strategies. A lifecycle–decision matrix was constructed to characterize application patterns.
Results
AI applications were concentrated in real-world clinical care × patient-level safety prediction and post-marketing × safety surveillance, using EHRs, spontaneous reporting systems, and clinical text. Common methods included gradient boosting, deep neural networks, graph neural networks, and natural language processing models. This concentration reflects structural incentives favoring safety-oriented applications with readily available data and lower decision liability. Evidence for treatment optimization, regulatory decision modeling, and evidence synthesis was limited. Most studies used internal validation; external validation and real-world deployment were uncommon, indicating early methodological maturity and limited translational readiness.
Conclusions
AI demonstrates strong potential to enhance drug safety—particularly in risk prediction and pharmacovigilance—but its use remains uneven across the lifecycle. By situating AI applications within explicit lifecycle stages and decision contexts, this review clarifies where progress has advanced, where translation has stalled, and why these gaps persist. Limited external validation and minimal real-world testing constrain clinical and regulatory adoption. These findings suggest that external validation and real-world testing may contribute to further advances in AI for drug safety.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- College of Pharmacy, Sunchon National University, Suncheon 57922, Republic of Korea.
- College of Pharmacy and Research Institute of Life and Pharmaceutical Sciences, Sunchon National University, Suncheon 57922, Republic of Korea.
ORCID-Profile: Miryoung Kim
Förderung
- Regional Innovation System & Education (RISE) program through the Jeollanamdo RISE center, funded by the Ministry of Education (MOE) and the Jeollanamdo, Repub…
Zitieren
APA
Kim, T. W., Park, S., & Kim, M. (2026). Artificial Intelligence for Drug Safety Across the Lifecycle and Decision Type: A Scoping Review. Pharmaceuticals, 19(2), 334. https://doi.org/10.3390/ph19020334
Vancouver
Kim TW, Park S, Kim M. Artificial Intelligence for Drug Safety Across the Lifecycle and Decision Type: A Scoping Review. Pharmaceuticals. 2026;19(2):334. doi:10.3390/ph19020334
BibTeX
@article{Kim2026,
author = {Kim, Tae Woo and Park, Sihyeon and Kim, Miryoung},
title = {Artificial Intelligence for Drug Safety Across the Lifecycle and Decision Type: A Scoping Review},
journal = {Pharmaceuticals},
year = {2026},
volume = {19},
number = {2},
pages = {334},
doi = {10.3390/ph19020334}
}
EUVIMED